Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Ductal carcinoma in situ that involves sclerosing adenosis: high frequency of bilateral breast cancer occurrence.

Yoshida A, Hayashi N, Akiyama F, Yamauchi H, Uruno T, Kikuchi M, Yagata H, Tsugawa K, Suzuki K, Nakamura S, Tsunoda H.

Clin Breast Cancer. 2012 Dec;12(6):398-403. doi: 10.1016/j.clbc.2012.08.002. Epub 2012 Oct 17.

PMID:
23083502
2.

Topographical, morphological and immunohistochemical characteristics of carcinoma in situ of the breast involving sclerosing adenosis. Two distinct topographical patterns and histological types of carcinoma in situ.

Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Shiraiwa M, Nishida C, Morita T, Sato Y, Hayashi T, Kato A, Aoyama H, Yoshikawa K.

Histopathology. 2011 May;58(6):835-46. doi: 10.1111/j.1365-2559.2011.03792.x. Epub 2011 Mar 14.

PMID:
21401704
3.

Breast Sclerosing Adenosis and Accompanying Malignancies: A Clinicopathological and Imaging Study in a Chinese Population.

Huang N, Chen J, Xue J, Yu B, Chen Y, Yang W, Shao Z, Wu J.

Medicine (Baltimore). 2015 Dec;94(49):e2298. doi: 10.1097/MD.0000000000002298.

4.

[Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].

Yang M, Xu SP, Ao QL.

Zhonghua Bing Li Xue Za Zhi. 2013 Apr;42(4):257-61. doi: 10.3760/cma.j.issn.0529-5807.2013.04.010. Chinese.

PMID:
23928534
5.

DCIS showing architectural distortion on the screening mammogram - comparison of mammographic and pathological findings.

Sekine K, Tsunoda-Shimizu H, Kikuchi M, Saida Y, Kawasaki T, Suzuki K.

Breast Cancer. 2007;14(3):281-4.

6.

Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.

Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM.

Ann Surg Oncol. 2011 May;18(5):1342-8. doi: 10.1245/s10434-010-1407-3. Epub 2010 Nov 2.

PMID:
21042943
7.

Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.

Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F.

Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.

PMID:
24275214
8.

Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G.

Ann Oncol. 2015 Apr;26(4):682-7. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.

PMID:
25600567
9.

Sonographic findings of high-grade and non-high-grade ductal carcinoma in situ of the breast.

Park JS, Park YM, Kim EK, Kim SJ, Han SS, Lee SJ, In HS, Ryu JH.

J Ultrasound Med. 2010 Dec;29(12):1687-97.

PMID:
21098839
10.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

11.
12.

Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.

Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.

Histopathology. 2007 Jun;50(7):866-74.

PMID:
17543076
13.

Is there a low-grade precursor pathway in breast cancer?

King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.

PMID:
21935747
14.

[Invasive carcinoma arising in breast microglandular adenosis: a clinicopathologic study of three cases and review of the literature].

Shui RH, Cheng YF, Yang WT.

Zhonghua Bing Li Xue Za Zhi. 2011 Jul;40(7):471-4. Review. Chinese.

PMID:
22088374
16.

The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.

Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller JE, Nisenbaum H, Czerniecki BJ, Zhang PJ.

J Surg Oncol. 2011 Oct;104(5):458-65. doi: 10.1002/jso.21973. Epub 2011 May 9.

17.

Ductal carcinoma in situ of the breast in Singapore: recent trends and clinical implications.

Tan KB, Lee HY, Putti TC.

ANZ J Surg. 2002 Nov;72(11):793-7.

PMID:
12437689
18.

Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes.

Kim MY, Kim HS, Choi N, Yang JH, Yoo YB, Park KS.

Clin Imaging. 2015 Nov-Dec;39(6):983-6. doi: 10.1016/j.clinimag.2015.06.006. Epub 2015 Jul 16.

PMID:
26259866
19.

Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT.

Breast Cancer Res Treat. 2013 Jun;139(3):639-47. doi: 10.1007/s10549-013-2598-7. Epub 2013 Jun 18.

20.

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):183-9. doi: 10.1016/j.clon.2011.09.008. Epub 2011 Sep 29.

PMID:
21958729

Supplemental Content

Support Center